Patents by Inventor Marc Donath

Marc Donath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY
    Publication number: 20220088144
    Abstract: The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin-1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Applicant: UNIVERSITÄTSSPITAL BASEL
    Inventor: Marc DONATH
  • SIRT1 POLYMORPHIC VARIANTS AND METHODS OF USE THEREOF
    Publication number: 20110113498
    Abstract: Provided herein are Sirt1 polymorphic variants having a substitution at amino acid residue 107 or nucleotide 373. In certain embodiments, the Sirt1 polypeptide variants have a L107P substitution and the nucleic acid variants have a T373C substitution. Genetic and/or biochemical testing may be performed to identify whether a patient carries one of the disclosed polymorphic variants. Based on the polymorphic variant the patient carries, a medical practitioner may administer an appropriate therapy, such as a sirtuin activator.
    Type: Application
    Filed: May 15, 2009
    Publication date: May 12, 2011
    Inventors: Christoph H. Westphal, Marc Donath, Peter Elliott, Michael Jirousek, Jill Milne
  • USE OF AN INTERLEUKIN 1 RECEPTOR ANTAGONIST AND/OR PYRROLIDINEDITHIOCARBAMATE FOR THE TREATMENT OR PROPHYLAXIS OF TYPE 2 DIABETES
    Publication number: 20090305992
    Abstract: Substances that inhibit the action of the members of the IL-1?/NF-?B pathway can be used for protecting and preserving ?-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 10, 2009
    Applicant: UNIVERSITY OF ZURICH
    Inventor: MARC DONATH
  • Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
    Patent number: 7572770
    Abstract: Substances that inhibit the action of the members of the IL-1?/NF-?B pathway can be used for protecting and preserving ?-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: August 11, 2009
    Assignee: University of Zurich
    Inventor: Marc Donath
  • Fuel reforming device
    Publication number: 20060079452
    Abstract: Substances that inhibit the action of the members of the IL-1?/NF-?B pathway can be used for protecting and preserving ?-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
    Type: Application
    Filed: June 25, 2003
    Publication date: April 13, 2006
    Inventor: Marc Donath